Johnson & Johnson Receives the US FDA’s EUA for COVID-19 Vaccine

 Johnson & Johnson Receives the US FDA’s EUA for COVID-19 Vaccine

Johnson & Johnson Receives the US FDA’s EUA for COVID-19 Vaccine

Shots:

  • The FDA has issued a EUA for a single-shot COVID-19 vaccine to prevent COVID-19 in individuals aged ≥18yrs. The company plans to file BLA to the US FDA in 2021
  • The EUA is based on a P-III ENSEMBLE study that demonstrated 85% efficacy in preventing severe disease across all regions and protect against COVID-19 related hospitalization and death, across countries with different variants
  • The EUA follows a unanimous vote by the US FDA’s VRBPAC on Feb 26, 2020. The company plans to deliver 100M doses to the US in the H1’21

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Law.com

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post